CBTCabot Corporation
Is it growing?
Growth is fading: revenue shrinking (−5% year on year), earnings down −53% year on year, and operating margin narrowing (−3.0 points).
Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +3% a year.
Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.
Trailing-twelve-month operating margin, 13.7% now against 16.7% a year earlier.
All from SEC EDGAR, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.
Is CBT growing?
Cabot Corporation has grown revenue −3.8% a year over three years and 2.8% a year over five, with earnings per share compounding at −12%.
Revenue growth, 3-year annual rate · Specialty Chemicals median +3.3% · shrinking · compounded from trailing twelve-month revenue
- Revenue growth, 5-year rate
- +2.8%
Revenue growth, 5-year rate · −3.8% over three · growth has slowed since the five-year average
- Earnings per share, 3-year rate
- −12%
Earnings per share, 3-year rate · revenue −3.8% · earnings lagged revenue: the growth is costing something
- Years of annual history on file
- 18
Years of annual history on file · FY2008 to FY2025, as filed
Details›
- Revenue FY2021
- $3.41B
- Revenue FY2022
- $4.32B
- Revenue FY2023
- $3.93B
- Revenue FY2024
- $3.99B
- Revenue FY2025
- $3.71B
Annual income statements as filed with the SEC.